ISA Completes Enrolment in Randomized Double Blind Phase 2 Clinical Trial of ISA101b in HPV16 induced Oropharyngeal Cancer

Professor Melief to receive 2022 SITC Pedro J. Romero Award

ISA to present key learnings for cancer vaccine development at the ESMO Immuno-Oncology Congress

ISA Pharmaceuticals Receives Fast Track Designation for Lead Product ISA101b

ISA Pharmaceuticals Commences Patient Treatment in Third Phase 2 Clinical Trial with the Combination of ISA101b and Libtayo® (cemiplimab)

ISA Pharmaceuticals Co-authors Publication in Nature Reviews Cancer on Therapeutic Cancer Vaccines

First Patient Treated in Phase II Combination Trial of ISA Pharmaceuticals’ Lead Immunotherapy ISA101b with Keytruda®

ISA Pharmaceuticals to present at the 33rd International Papillomavirus Conference & Basic Science

ISA Pharmaceuticals Strengthens Strategic Immuno-Oncology Collaboration with Regeneron